Bio-Rad (NYSE: BIO) EVP Engelhardt sells 550 A shares in open market

Rhea-AI Filing Summary

Bio-Rad Laboratories executive Eva Anette Engelhardt, EVP and President of the Clinical Diagnostics Group, reported an open-market sale of Bio-Rad A Common Stock. She sold 550 shares on May 11, 2026 at a price of $246.54 per share. After this transaction, she directly holds 346 shares of Bio-Rad A Common Stock.

Insider Trade Summary

Net Seller: 550 shares ($135,597)

Net Sell 1 txn

Insider ENGELHARDT EVA ANETTE

Role EVP, President, CDG

Sold 550 shs ($136K)

Type	Security	Shares	Price	Value
Sale	Bio-Rad A Common Stock	550	$246.54	$136K

Holdings After Transaction: Bio-Rad A Common Stock — 346 shares (Direct, null)

Footnotes (1)

Key Figures

Shares sold: 550 shares Sale price: $246.54 per share Shares owned after transaction: 346 shares +2 more

5 metrics

Shares sold 550 shares Open-market sale of Bio-Rad A Common Stock on May 11, 2026

Sale price $246.54 per share Price for Bio-Rad A Common Stock in reported sale

Shares owned after transaction 346 shares Direct holdings of Bio-Rad A Common Stock after sale

Transaction code S Sale in open market or private transaction

Net share change -550 shares Net-sell direction from transactionSummary

Key Terms

open-market sale, Bio-Rad A Common Stock, non-derivative, Form 4

4 terms

open-market sale financial

"The transaction is described as an open-market sale of Bio-Rad A Common Stock."

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Bio-Rad A Common Stock financial

"The security title is listed as Bio-Rad A Common Stock in the transaction."

non-derivative financial

"The transaction type is categorized as non-derivative for this equity sale."

Form 4 regulatory

"The insider transaction is disclosed in a Form 4 filing."

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ENGELHARDT EVA ANETTE

(Last) (First) (Middle)

C/O BIO-RAD LABORATORIES, INC.

1000 ALFRED NOBEL DRIVE

(Street)

HERCULES CALIFORNIA 94547

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BIO-RAD LABORATORIES, INC. [ BIO BIO.B ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, President, CDG

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Bio-Rad A Common Stock	05/11/2026		S		550	D	$246.54	346	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	/s/ Eva Anette Engelhardt	05/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did BIO executive Eva Anette Engelhardt report?

Eva Anette Engelhardt reported an open-market sale of Bio-Rad A Common Stock. She sold 550 shares at $246.54 per share and, following the transaction, holds 346 shares directly, according to the disclosed Form 4 insider trading report.

How many BIO shares did Eva Anette Engelhardt sell and at what price?

She sold 550 shares of Bio-Rad A Common Stock at $246.54 per share. The transaction was reported as an open-market sale, indicating the shares were sold into the public market rather than via a private arrangement.

How many BIO shares does Eva Anette Engelhardt own after the reported sale?

After the reported sale, Eva Anette Engelhardt directly owns 346 shares of Bio-Rad A Common Stock. This post-transaction holding reflects the remaining stake disclosed in the Form 4 following her 550-share open-market sale.

What role does Eva Anette Engelhardt hold at Bio-Rad Laboratories (BIO)?

Eva Anette Engelhardt serves as Executive Vice President and President of the Clinical Diagnostics Group at Bio-Rad Laboratories. Her position makes her a corporate officer, which requires reporting her equity transactions in company stock on Form 4.

Was the BIO insider transaction classified as a buy or a sell?

The transaction was classified as a sell. The Form 4 identifies it with transaction code “S” and describes it as an open-market sale, meaning shares were disposed of rather than acquired by the reporting executive.